The COVID-19 pandemic has put clinical research and how it is organised, implemented, and disseminated under scrutiny, and has revealed not only capabilities, but also shortcomings and inefficiencies. Many of these observations reflected or magnified problems that preceded the pandemic in many areas of medicine and are likely to remain relevant in the years that follow. For example, it has been highlighted that more than 95% of clinical trials on COVID-19 were underpowered or poorly designed and thus had no possibility of providing meaningful evidence. 1 This problem sounds familiar to anybody observing the clinical trials landscape in psychiatry.

Read the article:


  1. Bugin K, Woodcock J,Trends in COVID-19 therapeutic clinical trials. Nat Rev Drug Discov. 2021; 20254-255


Please Sign in (or Register) to view further.